Please login to the form below

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’status by the European Medicines Agency (EMA). ... Ionis' C Frank Bennett. "PRIME designation for

Latest news

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

However the company’s consumer and medical devices divisions are still in the doldrums. ... researchers’time). Many of the proposed projects address brain disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

However the company’s consumer and medical devices divisions are still in the doldrums. ... researchers’time). Many of the proposed projects address brain disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major
UniQure’s starts pivotal haemophilia B gene therapy trial

rare inherited disease lipoprotein lipase deficiency (LPLD) in 2012. ... in development for Huntington’s disease, a neurodegenerative disorder with no approved therapies.
EMA hands UniQure orphan status first in Huntington's

Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure ’s candidate fit the bill, not least because there are no currently approved
FDA grants orphan drug status to UniQure’s Huntington’s Disease treatment

FDA grants orphan drug status to UniQure’ s Huntington’ s Disease treatment. ... Dutch biotech UniQure has won orphan drug designation (ODD) for its investigational treatment for Huntington’s Disease, a rare, inherited neurodegenerative disorder

More from news
Approximately 4 fully matching, plus 32 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.
Deal Watch May 2016

Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.
Medius Deal Watch table for February 2015

Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor
Deal Watch table for April 2013

480. Isis Pharmaceuticals/ Roche. Collaboration. To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
Pharma deals during April 2013

These deals, along with that announced with Moderna Therapeutics (messenger RNA therapies) and the purchase of AlphaCore (phase I programme for cardiovascular disease) earlier in the year exemplify AZ's focus ... Isis/ Roche. Isis, another biotech with a

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

uniQure appoints chief executive officer

This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. “ ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

VCCP Health

Not only do they bring experience working on Rx accounts such as the immunology biosimilar portfolio for Novartis, but passion and expertise for animal health, disease awareness and charity work. ... 2016, Echoes of the past, Huntington's Disease (Teva).
Use of biomarkers in marketing

pathway. When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’ s disease and Alzheimer’ s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very similar

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Team Lead: Competitive Salary

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Director: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Project / Account Manager (Medical Education): Salary TBC

Associate Medical Director: Highly Competitive

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director – Global Healthcare PR: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Director Healthcare PR Communications: Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Executive – Medical Communications: Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Director – Head of Public Affairs: Neg

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Consultant Health Economics - London / Oxford: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Associate Medical Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...